Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine by Levine, Myron M
Vaccines represent the epitome of a preventive strategy 
to  control  disease  [1,2].  In  the  individual,  they  confer 
direct  protection  and,  if  high  enough  immunization 
coverage  of  a  population  is  achieved,  unimmunized 
people may also be protected, indirectly, through ‘herd 
immunity’ [3,4]
as measles and polio vaccines, has interrupted indigenous 
transmission  of  those  diseases  in  entire  regions  of  the 
globe [5-8]. And one disease, smallpox, has been com-
pletely eradicated from the human population through 
the  epidemiologically  sound  use  of  smallpox  vaccine 
[9,10].
In  developing  countries,  where  two-thirds  of  the 
world’s population live, infectious diseases cause most of 
the mortality among children under 5 years of age [11] 
and constitute major health problems in older children 
and  adults.  Vaccines  are  among  the  most  promising 
inter  ventions  to  diminish  the  burden  of  speciﬁc  infec-
tions in populations in developing countries [12-15].
The special advantages of oral vaccines
Oral vaccines are particularly attractive for immunizing 
populations in developing countries for several reasons. 
First,  contaminated  needles  and  syringes  are  major 
problems both for health workers and for environmental 
safety in many developing countries where there is a high 
prevalence of HIV and hepatitis B and C [16-18]. Because 
they  obviate  the  need  for  needles  and  syringes,  oral 
vaccines allow less qualiﬁed health workers to carry out 
immunization.  Second,  the  simple  logistics  of  oral 
vaccines are highly compatible with mass immunization 
campaigns [19,20]. Lastly, in most societies both adults 
and  children  generally  prefer  an  oral  vaccine  to  a 
parenteral injection.
Despite the attractions of oral vaccines for developing 
countries, many oral vaccines, both live and non-living, 
have proven to be less immunogenic or less protective 
when administered to infants, children or adults living in 
low  socioeconomic  conditions  in  less-developed  coun-
tries than they are when used in industrialized countries 
barrier’  to  successful  immunization  of  people  in  less 
developed countries who receive oral vaccines. Here, I 
review this phenomenon, provide examples and possible 
explanations, and oﬀer suggestions for establishing the 
basis of the phenomenon.
Immune responses to oral vaccines in developing 
countries
A prototype: Sabin oral polio vaccine
trivalent polio vaccine (tOPV), which eliminated trans-
mission of wild-type polioviruses in the Americas [21], 
the Western Paciﬁc [22] and Europe [22] and has been 
the  linchpin  of  the  Global  Polio  Eradication  Initiative 
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Hope of Progress[23,24]. Of the three poliovirus serotypes (types 1 to 3), 
tOPV has interrupted transmission of type 2 poliovirus 
globally since 1999.
Despite the remarkable milestones of disease control 
achieved  with  tOPV,  it  has  been  recognized  since  the 
1960s that tOPV seems to be poorly and inconsistently 
immunogenic  in  some  developing  country  populations 
[25-31]. Diminished immunogenicity has been a particu-
larly vexing problem in the states of Uttar Pradesh and 
Bihar in India [32,33], from which wild-type polioviruses 
have  been  disseminated  to  other  states  in  India  and 
elsewhere in South Asia. By late 2005, the average child 
under  5  years  of  age  in  Bihar  and  Uttar  Pradesh  had 
received about 15 doses of OPV compared with about 10 
doses  for  children  of  the  same  age  elsewhere  in  India 
[34].  However,  because  of  diminished  immunogenicity, 
only an estimated 71% of children under age 5 years in 
these  two  states  were  successfully  immunized  against 
polio, compared with 85% of children elsewhere in India 
[34]. Diminished immune responses in children in these 
areas of India are correlated with poor sanitation, a high 
prevalence of diarrheal illness at the time of vaccination, 
competing enteric viruses and competition of type 2 with 
types 1 and 3 vaccine viruses [34]. Type 2 Sabin OPV 
strain colonizes the intestine better and is considerably 
more  immunogenic  than  types  1  or  3.  For  this  reason 
tOPV is formulated to contain less type 2 virus than the 
other two serotypes (ratio of 106:105:105.8 infectious units 
per  dose)  [35]  to  try  and  mute  its  dominance. 
Nevertheless,  in  some  developing  country  populations, 
including Uttar Pradesh and Bihar, it was necessary to 
change  from  use  of  tOPV  in  mass  campaigns  to  the 
selective use of monovalent type 1 and 3 vaccines or to 
bivalent type 1+3 vaccine to improve immune responses 
to these serotypes and to interrupt transmission [34,35].
Other oral vaccines with diminished immunogenicity or 
Table  1  lists  various  oral  vaccines  for  which  data  from 
clinical  trials  have  demonstrated  either  a  diminished 
immune response or lower eﬃcacy in developing countries 
than in industrialized country populations. Besides Sabin 
polio vaccine [25-31], these oral vaccines include rotavirus 
vaccines  [36-40],  CVD  103-HgR  live  cholera  vaccine 
[41-44], B subunit-inactivated Vibrio cholerae whole cell 
combination vaccine [45] and SC602 live Shigella ﬂexneri 
2a  vaccine  [46,47]
include both viral and bacterial and both live and non-
living  vaccines.  Moreover,  the  pheno  menon  has  been 
observed in all age groups, from young infants to adults. 
To maximize the protective eﬀects that can be achieved 
with  oral  vaccines  in  developing  countries,  it  will  be 
important  to  understand  why  immune  responses  and 
eﬃcacy tend to be lower in such target populations than in 
populations in industrialized countries.
Oral vaccines in young infants
Some common factors probably contribute to lowering 
the  immunogenicity  and  eﬃcacy  of  live  oral  vaccines 
among  people  of  all  ages  in  developing  countries. 
However,  there  are  special  confounding  factors  in  the 
case of young infants. In that age group, there is likely to 
be some level of immunity due to maternal serum IgG 
antibodies transferred in utero, and to breast milk, which 
contains  maternal  secretory  immunoglobulin  A  (sIgA) 
antibodies [48], immune cells and non-speciﬁc protective 
factors, such as lactoferrin [49,50] and oligosaccharides 
[51]
and modulate responses to vaccines.
Early  studies  with  tOPV,  RIT  4237  rotavirus  vaccine 
[36], tetravalent rhesus reassortant rotavirus vaccine at 
  Target ages at which diminished     
  immunogenicity or protection  Geographic locations   
Oral vaccine  was observed  where observed  References
Sabin polio vaccine strains  Infants, toddlers, preschool children,   India, sub-Saharan Africa  [25-33] 
  school-age children
RIT 4237 rotavirus  Infants  Gambia  [36]
Rotashield rotavirus vaccine   Infants  Brazil and Peru  [37,125] 
(104 plaque forming unit dosage)
Rotarix attenuated rotavirus  Infants  Malawi, South Africa, Bangladesh  [38]
Rotateq pentavalent attenuated rotavirus  Infants  Ghana, Kenya, Mali  [39]
MMU18006 (monovalent Rhesus rotavirus strain)  Infants  Pakistan  [40]
CVD 103-HgR live cholera strain  24-59 months; 5-9 years; adults  Indonesia, Thailand, Peru, Ecuador  [41-43,64]
Dukoral non-living cholera vaccine   1-12 years  Nicaragua  [45] 
(killed V. cholerae O1 plus B subunit)
SC602 attenuated   strain  Toddlers and school age children  Bangladesh  [46,47]
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candidate rotavirus vaccine strains [40] indicated a barrier 
to  oral  immunization.  Two  new  rotavirus  vaccines, 
Rotarix, the monovalent human G1P[8] strain attenuated 
by multiple passages in tissue culture [53], and Rotateq, a 
pentavalent  vaccine  based  on  reassortant  bovine 
rotavirus expressing human rotavirus surface proteins G1 
to 4 and P[8] [54], have been shown to be safe, immuno-
genic  and  highly  protective  against  severe  rotavirus 
gastroenteritis in large-scale, placebo-controlled efficacy 
trials  in  infants  in  North  America,  Europe  and  South 
America. However, when tested in efficacy trials in Africa 
and Asia, these two vaccines showed much lower efficacy 
[38,39]. The level of efficacy tended to correlate with the 
level  of  development  of  the  population  in  which  the 
vaccines  were  tested.  Although  this  may  reflect 
environmental influences such as competing enteric viral, 
bacterial or protozoan infections, it is likely that higher 
titers of breast milk IgA and maternally derived serum 
IgG antibodies against rotavirus also played a role in the 
places where vaccine efficacy was lowest.
Oral vaccines in older age groups
Various  oral  vaccines  have  demonstrated  diminished 
immunogenicity or efficacy in older age groups, including 
in  pre-school  and  school-age  children  and  adults.  By 
focusing on vaccines in these age groups, it is possible to 
identify and study environmental and host factors with-
out the confounding effects of breast milk and maternal 
antibodies. The vaccine that has been most intensively 
studied for these factors is live oral cholera vaccine strain 
CVD 103-HgR, a genetically engineered vaccine derived 
from a wild-type V. cholerae O1 classical biotype, Inaba 
serotype strain. In this vaccine, 94% of the gene encoding 
the enzymatically active A subunit of cholera toxin has 
been deleted and a gene encoding mercury ion resistance 
inserted  into  the  hemolysin  A  locus  as  an  indelible 
marker [55-57]. Our experience, and that of other groups, 
with CVD 103-HgR is reviewed below to illustrate how 
factors  associated  with  diminished  immunogenicity  to 
oral vaccines in developing country populations can be 
identified  and  examined  in  order  to  devise  ways  to 
overcome the barrier.
The CVD 103-HgR live oral cholera vaccine as a 
paradigm
Two O serogroups of V. cholerae, O1 and O139, can cause 
epidemics of cholera gravis. V. cholerae O1 is by far the 
more important as O139 infections are found in just a 
few areas of Asia (where they are responsible for only a 
few percent of cases) and O139 has not been reported 
from Africa. Two biotypes of V. cholerae O1 exist, El Tor 
and classical, although presently only El Tor strains are 
prevalent.  Recently,  highly  virulent  El  Tor  strains  have 
emerged that produce classical biotype cholera entero-
toxin.  Within  each  biotype  of  O1  are  found  two  main 
serotypes, Inaba and Ogawa. For a cholera vaccine to be a 
useful  public  health  tool,  it  must  protect  against  both 
serotypes  and  biotypes.  In  North  American  adults,  a 
single oral dose of about 5 × 108 colony forming units 
(cfu)  of  CVD  103-HgR  elicits  significant  (four-fold  or 
greater)  rises  in  serum  vibriocidal  antibody  (that  is, 
seroconversion) in over 90% of those vaccinated [56,58] 
and vaccine organisms are excreted by about 25% [56,58]. 
A  single  dose  of  CVD  103-HgR  significantly  protects 
North Americans against cholera caused by V. cholerae 
O1 of either classical or El Tor biotype and either Inaba 
or Ogawa serotype [56,59-61].
The first study in a developing country examining the 
safety and immunogenicity of CVD 103-HgR was carried 
out among young adult students on a Research Isolation 
Ward  at  Mahidol  University,  Bangkok,  Thailand  [62], 
with  immunogenicity  results  closely  resembling  those 
seen in healthy North Americans and Europeans. There-
fore,  bolstered  by  the  promising  results  of  this  (small) 
trial,  a  pediatric  study  was  initiated  in  children  5  to 
in  North  Jakarta,  Indonesia  [41]  (Figure  1a).  In  these 
children, the 5 × 108 cfu dose of CVD 103-HgR that had 
been so highly immunogenic in North American [56,58] 
and  Swiss  [63]  adults  and  higher  socioeconomic  level 
Thai university students [62] elicited significant increases 
in serum vibriocidal antibody in only 16% of the 5- to 
9-year-old  Indonesian  children  living  in  poverty  [41]. 
This was the first demonstration that diminished immuno-
genicity in developing country situations could also be 
encountered  with  oral  bacterial  vaccines  [41],  as  had 
been recognized for many years with oral viral vaccines.
Fortunately, by administering a tenfold higher dose of 
CVD 103-HgR (5 × 109 cfu) to children 5 to 9 years of age 
in North Jakarta, it was possible to achieve a high rate of 
seroconversion [41]. Moreover, the few non-responders 
were shown to be children who had high baseline titers of 
serum vibriocidal antibody and therefore were apparently 
already  immune  to  cholera.  Results  with  children  2  to 
4 years of age living in the same area were similar [64]. In 
studies with both adults and children, those who did not 
seroconvert had a significantly higher baseline vibriocidal 
titer than those who did seroconvert [41-43,64], indicat-
ing that such individuals are already immune and their 
serum titers are not typically boosted by vaccination.
It is worth noting that oral vaccines are expected to 
elicit locally produced intestinal antibodies and tests of 
serum antibodies do not detect these local antibodies. It 
is thus conceivable that intestinal antibodies may have 
increased  in  these  studies.  Indeed,  it  has  long  been 
surmised that rises in serum vibriocidal antibodies serve 
as a proxy for the elicitation of immune responses in the 
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9 years of age living in a squalid, cholera-endemic slum small intestine. It is also possible that some individuals 
may have baseline intestinal immunity not reflected by an 
elevated serum vibriocidal titer.
A  series  of  additional  immunogenicity  studies  with 
CVD  103-HgR  were  undertaken  in  Asia  [42],  South 
America [43,65-69] (after the El Tor pandemic of cholera 
reached that continent in 1991) and Africa [70]. From 
this  composite  of  clinical  trials,  we  identified  several 
factors that modulated the magnitude of the vibriocidal 
antibody response. The first of these is prior exposure to 
V.  cholerae  O1,  resulting  in  high  baseline  vibriocidal 
antibody titers: titers are not usually boosted in individ-
uals  with  high  baseline  titers  [41-43,64].  The  second 
factor is blood group O: people with blood group O (a 
well  recognized  host  risk  factor  for  development  of 
cholera gravis [71,72]) mount stronger serum vibriocidal 
responses [66], especially if immunologically naïve - that 
is, with no prior exposure to V. cholerae O1. The third 
factor  is  socioeconomic  level:  populations  in  under-
privileged conditions show lower antibody titers, inde-
pen  dent of blood group or prior contact with V. cholerae 
O1  [42,43].  The  fourth  factor  is  small  bowel  bacterial 
overgrowth (SBBO) [44] that often accompanies environ-
mental enteropathy (see below) [73,74], which in turn is 
related  to  living  in  poverty-associated  fecally  contami-
nated conditions. The fifth factor is heavy infection with 
intestinal  helminths  [75,76].  The  sixth  factor  is  HIV 
status:  although  the  rates  of  seroconversion  are  not 
significantly different, the antibody titers of HIV-positive 
individuals  are  significantly  lower  than  those  of  HIV-
negative individuals [70].
To  achieve  high  seroconversion  rates  of  vibriocidal 
antibody  in  Peruvian  and  Thai  adults  living  in  under-
privileged conditions, as with Indonesian children living 
in poverty, it was necessary to give a tenfold higher dose 
(5 × 109 cfu) of CVD 103-HgR [41-43] than the dosage 
level (5 × 108 cfu) that was consistently immunogenic in 
North  Americans  and  Europeans  [56,58].  This  109  cfu 
dosage level was also well tolerated and immunogenic in 
pre-school children [64,67], toddlers [68] and infants as 
young as 3 months of age [68].
The role of environmental enteropathy and small 
bowel bacterial overgrowth
The  proximal  small  intestines  of  healthy  children  and 
adults  who  live  in  relatively  pristine  environments  in 
industrialized  countries  show  only  modest  bacterial 
loads, whether measured by aerobic and anaerobic culture 
or  by  molecular  techniques  based  on  analysis  of  16S 
rDNA  sequencing  of  DNA  from  appropriate  clinical 
specimens  [77,78].  Common  known  bacterial  genera 
identi  fied  include  Streptococcus,  Veillonella,  Neisseria, 
Gemella, Rothia and Hemophilus; in contrast, fecal genera, 
such as are found in the colon or terminal ileum (where 
microbiota  densities  are  enormous),  are  uncommon. 
Duodenal  biopsies  show  that  the  mucosa  of  healthy 
children is characterized histologically by the presence of 
long, finger-like villi, ample columnar epithelial cells, a 
crypt  to  villus  ratio  of  1:3  or  1:4,  less  than  25  intra-
epithelial lymphocytes per 100 columnar cells and only a 
moderate  number  of  mononuclear  cells  in  the  lamina 
propria (Figure 2). In contrast, the gut of children living 
in  poverty  in  developing  countries  often  reflects  their 
continual  exposure  to  fecally  contaminated  environ-
ments, and many such children have SBBO and ‘environ-
men  tal enteropathy’ [73,74,79-81].
The  term  environmental  enteropathy  was  coined  by 
Fagundes  Neto  [73,74,80]  to  describe  a  syndrome  that 
includes  non-specific  histopathological  and  functional 
changes of the small intestine in children of poor families 
living in conditions lacking basic sanitary facilities and 
chronically exposed to fecal contamination (Figure 1b). 
Figure 1. Cholera-endemic living conditions. (a) Conditions 
of ramshackle housing, poor sanitation and widespread fecal 
contamination prevalent in North Jakarta in the early 1990s when 
phase 2 pediatric clinical trials with CVD 103-HgR live oral cholera 
vaccine were carried out. (b) Similar conditions of inadequate 
housing, lack of sanitation and fecally contaminated surface waters 
in a favella (periurban slum) in São Paulo, Brazil of the type in which 
environmental enteropathy was first described by Fagundes Neto. 
Photograph kindly provided by Ulysses Fagundes Neto, Universidade 
Federal de São Paulo.
(a)
(b)
Levine BMC Biology 2010, 8:129 
http://www.biomedcentral.com/1741-7007/8/129
Page 4 of 10The prominent histopathological features of environ  men-
tal enteropathy include blunted villi, abnormal crypt to 
villus  ratio,  an  increased  number  of  intraepithelial 
lymphocytes and a marked increase of lymphocytes and 
plasmacytes in the lamina propria (Figure 3a,b). A key 
feature of environmental enteropathy is the presence of 
SBBO  that  includes  fecal  bacterial  species  usually 
restricted  to  the  terminal  ileum  and  colon.  Another 
salient  feature  of  environmental  enteropathy  is  its  dis-
appearance over time following the individual’s transfer 
to a clean environment characterized by improved food 
hygiene  and  modern  sanitation  [80].  Environmental 
enteropathy  is  similar  (and  perhaps  identical)  to  the 
syndrome of ‘tropical enteropathy’ described by Linden-
baum et al. [82] in US Peace Corps volunteers who lived 
among  indigenous  populations  for  about  two  or  more 
years,  often  in  conditions  characterized  by  heavy  fecal 
contamination. The intestinal lesions observed in most of 
these young adults also slowly returned to normal several 
months after the volunteers returned to the USA [82].
The  presence  of  SBBO  can  be  detected  by  having 
fasting  children  ingest  the  disaccharide  lactulose  and 
detecting H2 in expired breath by gas chromatography at 
various time points; measurements are typically made at 
baseline  and  15,  30,  40,  60,  90  and  120  minutes  after 
ingestion  of  the  lactulose  [44,80,83].  Human  intestinal 
enzymes cannot cleave lactulose but bacterial enzymes 
can.  Therefore,  the  detection  of  H2  in  ‘small  bowel’ 
specimens - that is, those taken 15 or 30 minutes after 
lactulose  ingestion  -indicates  SBBO  [44,80,83].  The 
advantage  of  the  lactulose  breath  H2  test  is  that  it  is 
amenable to field studies involving hundreds of children 
[44,80,83].
When the relationship between SBBO and vibriocidal 
response  to  CVD  103-HgR  was  investigated  in  202 
fasting Chilean schoolchildren aged 5 to 9 years who had 
lactulose breath H2 tests one day before ingesting CVD 
103-HgR  [44],  florid  small  bowel  overgrowth  was 
observed in 10 out of 178 analyzable children (5.6%), and 
logistic regression analysis showed that increased peak 
breath H2 at ‘small bowel’ time points was associated with 
Figure 2. Normal intestinal mucosa. Biopsy of the second portion 
of the duodenum of an 8-year-old US child showing normal histology 
of the intestinal mucosa. Long, finger-like villi and relatively shallow 
crypts are evident. The villi are populated with columnar epithelial 
cells (enterocytes) that have brush borders containing enzymes 
for digestion and absorption; mucus-producing goblet cells are 
interspersed among the enterocytes. Less than 20 intraepithelial 
lymphocytes per 100 enterocytes are present. Photomicrograph 
kindly provided by Steven Czinn, University of Maryland Medical 
Center.
Figure 3. Intestinal mucosa showing environmental 
enteropathy. (a) Biopsy of the distal duodenum of a 36-month 
old Brazilian child with environmental enteropathy. Moderate 
villous atrophy is seen with blunted, flat villi and enterocytes that 
seem somewhat cuboidal rather than columnar. Elongated crypts 
can be seen, which result in an abnormal crypt to villus ratio. Most 
prominent is the striking increase in the number of lymphocytes 
and plasmacytes present in the lamina propria. (b) Biopsy of the 
distal duodenum of another Brazilian pre-school age child with 
environmental enteropathy. The changes are as described for (a) but 
the villous blunting and hypercellularity within the lamina propria 
are even more prominent. Photomicrographs kindly provided by 
Ulysses Fagundes Neto, Universidade Federal de São Paulo.
(a)
(b)
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the interaction of peak breath H2 and weight (P = 0.02) 
[44].
SBBO  could  blunt  the  immune  response  to  CVD 
103-HgR  by  the  production  of  short  chain  fatty  acids 
(such as butyric and propionic acids) [84] or other small 
molecules  [85]  that  directly  inhibit  the  V.  cholerae  O1 
vaccine, thereby markedly decreasing the actual dose of 
vaccine organisms. Immune responses to cross-reacting 
surface  antigens  of  intestinal  flora  may  also  blunt  the 
vibriocidal response to CVD 103-HgR. Alternatively, the 
effect may be indirect. Individuals with SBBO typically 
have  abnormal  intestinal  architecture  [73,74]  and 
increased lymphocytes and plasmacytes in the mucosa 
[73,74], perhaps with activated T cells [86]. One possible 
explanation is that under conditions of repetitive expo-
sure to fecal contamination, the innate immune system of 
the  child’s  gut  is  maximally  activated  and  in  a  pro-
inflammatory  state.  This  may  constitute  an  important 
non-specific  defense  in  the  proximal  small  intestine, 
rendering it generally hostile to incoming bacterial (and 
viral and protozoal) pathogens. Indeed, this may be what 
allows many children to survive repeated exposures to 
enteric pathogens. By extrapolation, attenuated bacterial 
or viral oral vaccines must also face this hostile, innate 
immune  system-activated  ecologic  niche  when  they 
reach the proximal small intestine, resulting in inhibition 
of the vaccine organisms and poor induction of specific 
adaptive  immune  responses.  Live  vaccines  might  then, 
instead  of  activating  the  innate  immune  system  to 
enhance adaptive immune responses (as would happen in 
an industrialized country gut), be destroyed by an already 
highly activated innate immune response.
Supporting  this  hypothesis  is  the  observation  that 
although people in developing countries show moderate 
or high rates of seroconversion following ingestion of the 
109 cfu dosage level of CVD 103-HgR, they also show 
significantly lower rates of excretion of the vaccine strain 
[41,43,64,67,68]. It is increasingly recognized that normal 
gut  homeostasis  (including  gut  immunity)  involves 
‘crosstalk’  among  the  microbiota  present  in  the  outer 
layer of the mucus biofilm covering the mucosa, entero-
cytes and cells of the immune system [87-91].
An alternative explanation for the decreased immune 
responses  is  that  the  mononuclear  cell  hypercellularity 
observed in the mucosa of patients with environmental 
enteropathy may indicate altered regulatory T cell and 
dendritic cell function that contributes to dampening of 
immune responses [81,92,93]. It is possible that environ-
mental  enteropathy  modifies  the  proximal  small  bowel 
ecology so much that it begins to resemble the colon not 
only in its microbiota but in the immunological function-
ing of its mucosa (immune structures commonly form in 
chronically  infected  mucosa).  Collectively,  these  ideas 
may be considered the obverse of the ‘hygiene hypo  the-
sis’ - the widely popularized notion that the increasing 
prevalence of allergies in industrialized countries reflects 
a failure to develop the normal regulatory balance of the 
adaptive  immune  response  when  exposure  to  environ-
mental pathogens is limited [94-96].
Further evidence of a role for intestinal infection in the 
diminished  vibriocidal  antibody  response  to  the  CVD 
103-HgR vaccine has been gathered in studies on school 
age  children  in  rural  Ecuador  with  documented  heavy 
helminthic  (Ascaris  lumbricoides)  infection  [75,76]. 
These children were randomly allocated to receive two 
courses  of  an  anti-helminthic  (albendazole)  or  placebo 
and were then immunized with a single 5 × 108 cfu dose 
of CVD 103-HgR [75]. For children of blood group O, 
there  was  no  difference  in  the  vibriocidal  responses 
observed in the albendazole versus the placebo groups. 
However,  for  children  of  non-O  blood  groups,  those 
treated  with  albendazole  had  a  significantly  higher 
vibriocidal antibody response than those given placebo.
Extrapolating to other oral vaccines
Some  of  the  factors  that  seem  to  contribute  to  the 
diminished  immunogenicity  of  CVD  103-HgR  may  be 
relevant  to  other  oral  live  vaccines.  Live  oral  Shigella 
flexneri  2a  candidate  SC602  was  reactogenic  in  North 
American volunteers when ≥106 cfu were ingested [97]. 
However,  ingestion  of  a  lower,  better  tolerated  dose 
(104 cfu) was followed by heavy excretion, strong immune 
responses and protection against experimental challenge 
with wild-type S. flexneri 2a [97]. In contrast, when tested 
in a phase 1 trial in Bangladeshi toddlers, neither vaccine 
excretion nor immune responses were observed follow-
ing ingestion of 104, 105 or 106 cfu of SC602 [47].
Licensed  live  oral  typhoid  vaccine  Ty21a  may  be  a 
notable exception. This live oral vaccine does not elicit 
strong  (that  is,  high  titer)  serum  antibody  responses 
[98,99] but does stimulate intestinal IgA antibodies [100] 
as well as robust B [101] and T cell-mediated [102-105] 
immune  responses,  and  appropriate  formulations  and 
immuni  zation  schedules  of  Ty21a  have  conferred 
significant protection on school-age children for up to 
7  years  in  large-scale,  randomized,  controlled  efficacy 
trials in Egypt [106], Chile [107-110] and Indonesia [111]. 
This  may  be  a  function  of  the  way  Salmonella  Typhi 
interacts  with  the  small  intestinal  mucosa,  as  this 
organism effectively targets the M cells that overlie gut-
associated lymphoid tissue [112,113] and is then readily 
taken  up  by  the  underlying  dendritic  cells  and  macro-
phages.  Thus,  Ty21a  easily  and  rapidly  gains  access  to 
inductive sites of the immune system. This may hold true 
for several markedly more immunogenic modern recom-
binant S. Typhi single-dose vaccine candidates that are in 
development [114-117].
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Now that the poor response of many people in developing 
countries  to  a  variety  of  oral  vaccines  has  been  docu-
mented and widely recognized, a consensus is emerging 
that action should be initiated to study the phenomenon, 
with a view to counteracting the factors responsible for 
the intestinal barrier [118]. With respect to the role of 
SBBO and the alterations of the intestinal mucosa that 
characterize environmental enteropathy, there is much to 
be  done.  A  ﬁrst  step  should  be  to  separate  any  direct 
inhibitory  role  of  the  bacterial  ﬂora  itself,  whether  in 
mucus-associated  bioﬁlm  or  in  the  lumen,  from  the 
broader defects that may be consequent on the altered 
architecture  and  function  of  the  intestinal  mucosa.  A 
controlled  trial  should  be  undertaken  to  determine 
whether  temporarily  eliminating  SBBO  with  oral  anti-
biotics  before  oral  immunization  enhances  immune 
responses to the vaccine [119]. If this has a positive eﬀect, 
then  non-antibiotic  interventions  (such  as  competing 
probiotic bacteria) should be studied.
Giardia infections are highly prevalent among children 
in developing countries but are increasingly recognized 
not  to  be  associated  with  either  diarrhea  or  adverse 
nutritional  consequences  [120].  Nevertheless,  Giardia 
may have an impact on mucosal integrity and function 
would advocate a randomized, placebo-controlled trial in 
which  half  the  participants  receive  metronidazole  to 
eradicate Giardia before oral vaccination.
If eliminating SBBO with antibiotics or Giardia with 
metronidazole  has  no  impact,  then  ways  should  be 
explored  to  repair  the  integrity  and  function  of  the 
intestinal mucosa. Vitamin A modestly improved immune 
responses  to  type  1  poliovirus  vaccine  but  did  not 
enhance  serum  vibriocidal  responses  to  a  killed  oral 
cholera  vaccine  [121].  Two  studies  investigated  zinc 
supplementation  and  responses  to  a  non-living  oral 
cholera vaccine; one [121] showed slight improvement of 
vibriocidal  responses  following  zinc  supplementation, 
whereas  the  other  [122]
suggests that further evaluation of zinc is needed. Alanyl-
glutamine  may  improve  gut  integrity  in  patients  with 
environmental enteropathy [123]. Lastly, modifying the 
innate  immune  system  of  the  gut  in  relation  to  oral 
vaccination should be studied with increased stimulation 
(vaccine plus a mucosal adjuvant such as Escherichia coli 
double mutant LT [124]) to counteract possible tolerance, 
or with dampening of the innate immunity (vaccine plus 
a suppressive agent) to determine which approach, if any, 
has an ameliorating eﬀect.
Published: 4 October 2010
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